<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029973</url>
  </required_header>
  <id_info>
    <org_study_id>HAICDD</org_study_id>
    <nct_id>NCT05029973</nct_id>
  </id_info>
  <brief_title>HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Advanced Unresectable HCC</brief_title>
  <official_title>A Study to Evaluate the Efficacy and Safety of the Hepatic Arterial Infusion Chemotherapy(HAIC) Combined With Sintilimab and Bevacizumab Biosimilar in the First-Line Treatment of Patients With Advanced Unresectable Hepatocellular Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Evaluate the Efficacy and Safety of the Hepatic Arterial Infusion Chemotherapy(HAIC)&#xD;
      Combined With Sintilimab and Bevacizumab Biosimilar in the First-Line Treatment of Patients&#xD;
      With Advanced Unresectable Hepatocellular Carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">November 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 10, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate ( ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as proportion of patients who have a best response of CR or PR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the time from the date of treatment start to the date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Events Free Survival (EFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the time from enrollment to disease progression, recurrence or death (whichever occurs first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical conversion rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the incidence rate of patients that receive surgical resection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate of patients who accepted surgical resection</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the proportion of patients undergoing radical resection to the total patients accepted surgical resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response (pCR) rate of patients who accepted surgical resection</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the proportion of patients whose tumor and lymph node completely disappeared to the total patients accepted surgical resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0 and complications of surgery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HAIC Combined With Sintilimab and Bevacizumab Biosimilar</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAIC</intervention_name>
    <description>hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Hepatic Artery Infusion Chemotherapy</other_name>
    <other_name>FOLFOX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>200mg IV d1,Q3W</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>IBI308</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab Biosimilar</intervention_name>
    <description>15mg/kg IV d1,Q3W</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>IBI305</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent should be signed before implementing any trial-related&#xD;
             procedures;&#xD;
&#xD;
          -  Age ranges from 18 to 75 years old.&#xD;
&#xD;
          -  CNLC-IIIa and IIIb HCC based on the Criteria for diagnosis and treatment of&#xD;
             hepatocellular carcinoma (2019 edition)&#xD;
&#xD;
               -  The largest tumor lesion ≥ 7 cm;&#xD;
&#xD;
               -  Accompanied by macrovascular invasion (portal vein or hepatic vein tumor&#xD;
                  thrombus) and extrahepatic metastasis;&#xD;
&#xD;
               -  At least ≥ 1 measurable lesions per RECIST 1.1;&#xD;
&#xD;
               -  Child-Pugh grade A;&#xD;
&#xD;
               -  ECOG PS scores 0-1;&#xD;
&#xD;
          -  No prior therapy for HCC.&#xD;
&#xD;
          -  Expected survival time &gt; 6 months;&#xD;
&#xD;
          -  Sufficient organ functions, the subjects need to meet the following laboratory&#xD;
             indicators:&#xD;
&#xD;
               -  No blood transfusion, no use of hematopoietic stimulators (including g-csf,&#xD;
                  gm-csf, EPO and TPO) and infusion of human albumin preparations within 14 days&#xD;
                  prior to screening:Neutrophil absolute count ≥1.5×10^9/L;Platelet count ≥&#xD;
                  100×10^9/L;Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 × upper limit of normal (ULN); or total bilirubin &gt; ULN but&#xD;
                  direct bilirubin ≤ ULN&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤5 × ULN;&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 × ULN and creatinine clearance rate (calculated by&#xD;
                  Cockcroft-Gault formula) ≥ 60 ml/min;&#xD;
&#xD;
               -  International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 × ULN&#xD;
&#xD;
               -  Normal thyroid function, defined as thyroid stimulating hormone (TSH) within the&#xD;
                  normal range. If the baseline TSH exceeds the normal range, the subjects can also&#xD;
                  be included in the group in case total T3 (or FT3) and FT4 are within the normal&#xD;
                  range;&#xD;
&#xD;
               -  Myocardial enzyme spectrum should be within the normal range (if the investigator&#xD;
                  comprehensively judges that the simple laboratory abnormality is not clinically&#xD;
                  significant, the subject is also included);&#xD;
&#xD;
          -  Female subjects of childbearing age should receive a urine or serum pregnancy test and&#xD;
             the result is negative, 3 days prior to accept the first study drug administration&#xD;
             (day 1 of cycle 1). In case the urine pregnancy test result cannot be confirmed as&#xD;
             negative, a blood pregnancy test is required. Meanwhile, voluntary use of appropriate&#xD;
             contraceptive methods shall be taken during the observation period and within 8 weeks&#xD;
             of the last administration of the study drug; Women of non-bearing age are defined as&#xD;
             at least 1 year after menopause, or those who have undergone surgical sterilization or&#xD;
             hysterectomy; For males, appropriate contraceptive methods should be taken during the&#xD;
             observation period and within 8 weeks after the last dose of the study drug.&#xD;
&#xD;
          -  If there is a risk of pregnancy, all subjects (regardless of male and female) need to&#xD;
             adopt contraceptives with an annual failure rate of less than 1% during the entire&#xD;
             treatment period until 120 days after the last administration of the study drug (or&#xD;
             180 days after the last chemotherapeutic drug administration).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known as Inhibition of fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma&#xD;
             and HCC；Previous HCC recurrence；Hepatic encephalopathy has been clinically diagnosed&#xD;
             in the past 6 months .&#xD;
&#xD;
          -  Autoimmune hepatitis (requiring liver puncture).&#xD;
&#xD;
          -  History of organ transplantation or hepatic encephalopathy.&#xD;
&#xD;
          -  Diffuse hepatoma.&#xD;
&#xD;
          -  Clinical symptoms requiring drainage including pleural effusion, ascites, and&#xD;
             pericardial effusion.&#xD;
&#xD;
          -  History of nephropathy or nephrotic syndrome.&#xD;
&#xD;
          -  Bleeding from a varicose vein in the esophagus or gastric fundus caused by portal&#xD;
             hypertension in the past 6 months; Presence of severe (G3) varicose veins identified&#xD;
             by endoscopy 3 months prior to initial administration; Evidence of portal hypertension&#xD;
             (including imaging findings that the length of the spleen exceeds 10 cm and the&#xD;
             platelets lower than 100), with a high risk of hemorrhage assessed by the&#xD;
             investigator.&#xD;
&#xD;
          -  Arteriovenous thromboembolic events in the past 6 months, including history of&#xD;
             myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic&#xD;
             attack, pulmonary artery embolism, deep vein thrombosis or any other serious&#xD;
             thromboembolism. Implantable venous infusion port or catheter-derived thrombosis, or&#xD;
             superficial venous thrombosis, except for those with stable thrombosis after&#xD;
             conventional anticoagulation therapy.&#xD;
&#xD;
          -  Severe bleeding tendency or coagulation dysfunction, or under thrombolytic therapy.&#xD;
&#xD;
          -  Acceptance of preventive use of low-dose low-molecular-weight heparin (such as&#xD;
             Enoxaparin 40 mg/day), except for vitamin K antagonists (such as warfarin).&#xD;
&#xD;
          -  Requiring long-term medication for the inhibition of platelet function, such as&#xD;
             aspirin, dipyridamole or clopidogrel.&#xD;
&#xD;
          -  Uncontrollable hypertension, systolic blood pressure &gt; 140 mmHg or diastolic blood&#xD;
             pressure &gt; 90 mmHg after optimized medical treatment, history of critical hypertension&#xD;
             or hypertensive encephalopathy.&#xD;
&#xD;
          -  Symptomatic congestive heart failure (New York Heart Association class II-IV),&#xD;
             symptomatic or poorly controlled arrhythmia, congenital long QT syndrome history or&#xD;
             QTc &gt; 500 ms corrected at screening (calculated using the Fridericia method).&#xD;
&#xD;
          -  History of gastrointestinal perforation and or fistula, intestinal obstruction&#xD;
             (including incomplete intestinal obstruction requiring parenteral nutrition),&#xD;
             extensive bowel resection (partial colectomy or extensive small bowel resection,&#xD;
             complicated by chronic diarrhea), Crohns disease, ulcerative colitis, or long-term&#xD;
             chronic diarrhea in the past 6 months.&#xD;
&#xD;
          -  Received major surgery (craniotomy, thoracotomy or laparotomy) or unhealed wounds,&#xD;
             ulcers or fractures within 4 weeks prior to the first administration, except for&#xD;
             received tissue biopsy or other minor surgery within 7 days prior to the first&#xD;
             administration, venipuncture catheterization for intravenous infusion.&#xD;
&#xD;
          -  Past and present history of lung diseases including pulmonary fibrosis, interstitial&#xD;
             pneumonia, pneumoconiosis, drug-related pneumonia, and severely impaired lung&#xD;
             functions.&#xD;
&#xD;
          -  Acute or chronic active hepatitis B or C infection.&#xD;
&#xD;
          -  Active tuberculosis (TB), under anti-tuberculosis treatment or anti-tuberculosis&#xD;
             treatment within 1 year prior to the first administration.&#xD;
&#xD;
          -  Infected by human immunodeficiency virus (HIV) and known syphilis infection.&#xD;
&#xD;
          -  Severe infections in active phase or poorly controlled clinically. Severe infection&#xD;
             within 4 weeks prior to the first administration.&#xD;
&#xD;
          -  Have used immunosuppressive drugs within 4 weeks before the first dose&#xD;
&#xD;
          -  Received live attenuated vaccines within 4 weeks before the first dose or plan to&#xD;
             receive live attenuated vaccines during the study period&#xD;
&#xD;
          -  Received Chinese medicine with anti-tumor indications, or received drugs with&#xD;
             immunomodulatory effect within 2 weeks before the first administration&#xD;
&#xD;
          -  Received any anti-PD-1 antibody, anti-PD-L1/L2 antibody, anti-CTLA4 antibody, or other&#xD;
             immunotherapy&#xD;
&#xD;
          -  Allergic to Sintilizumab, Bevacizumab preparations and excipients, or had severe&#xD;
             allergic reactions to other monoclonal antibodies in the past&#xD;
&#xD;
          -  Received treatment from other clinical trials within 4 weeks before the first dose&#xD;
&#xD;
          -  Female subjects who are pregnant or breastfeeding&#xD;
&#xD;
          -  Other conditions that the subjects are not suitable to participate in this study&#xD;
             according to the judgment of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Huikai Li, MD</last_name>
    <phone>862223340123</phone>
    <phone_ext>3091</phone_ext>
    <email>lihuikai@tjmuch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huikai Li, MD</last_name>
      <phone>+862223340123</phone>
      <phone_ext>3091</phone_ext>
      <email>lihuikai@tjmuch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 29, 2021</study_first_submitted>
  <study_first_submitted_qc>August 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Sintilimab</keyword>
  <keyword>Bevacizumab Biosimilar</keyword>
  <keyword>HAIC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

